We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by... Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. Show more
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal...
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation PR...
Indivior Announces Q4 / FY 2023 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/...
Indivior Announces Q3 2023 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC...
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals PR Newswire RICHMOND, Va., Oct. 11, 2023 - Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment...
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada PR Newswire RICHMOND, Va., Sept. 26, 2023 Rates of...
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims PR Newswire RICHMOND, Va., Aug. 21, 2023 RICHMOND, Va., Aug. 21, 2023 /PRNewswire/...
Indivior Announces Q2/H1 2023 Financial Results PR Newswire SLOUGH, United Kingdom, and RICHMOND, Va., July 27, 2023 SLOUGH, United Kingdom, and RICHMOND, Va., July 27, 2023 /PRNewswire/...
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence PR Newswire RICHMOND, Va., June 14, 2023 RICHMOND...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.67 | 3.87731481481 | 17.28 | 18.45 | 17.23 | 150822 | 17.69934342 | CS |
4 | -3.47 | -16.1998132586 | 21.42 | 21.87 | 17.12 | 125003 | 18.77234926 | CS |
12 | 0.13 | 0.729517396184 | 17.82 | 23.22 | 16.44 | 143610 | 20.18454567 | CS |
26 | -2.24 | -11.0946012878 | 20.19 | 23.22 | 14.3809 | 93788 | 19.14331951 | CS |
52 | -8.55 | -32.2641509434 | 26.5 | 26.5 | 14.3809 | 57810 | 19.46860182 | CS |
156 | -8.55 | -32.2641509434 | 26.5 | 26.5 | 14.3809 | 57810 | 19.46860182 | CS |
260 | -8.55 | -32.2641509434 | 26.5 | 26.5 | 14.3809 | 57810 | 19.46860182 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions